IL-1 was effective in only 28.6% of patients (15), while IL-6 was effective in chronic recurrent multifocal osteomyelitis (CRMO) but did not significantly improve skin symptoms (42). This evidence concerns the gene IL6 and chronic recurrent multifocal osteomyelitis.